Rising Androgens in Pregnancy With Classic CAH: How Much to Increase Hydrocortisone
A single patient whose own androgen control, unrelated to any fetal CAH risk, drifts upward in pregnancy in a way that tests how much a physiologic-range dose adjustment should be trusted against a fetal-exposure literature built on a different clinical scenario.
Naomi F., a 31-year-old classic CAH patient now twenty-two weeks into a pregnancy she and her husband spent two years trying to conceive, has been stable for most of her adult life on hydrocortisone 15–10–5 mg, chosen specifically over prednisolone on the reasoning set out in Speiser et al.'s Endocrine Society congenital adrenal hyperplasia guideline: placental 11β-hydroxysteroid dehydrogenase type 2 inactivates hydrocortisone far more completely, limiting fetal exposure to a degree prednisolone's structure doesn't allow. She works as a labor and delivery nurse herself, a detail she brings up with a mix of humor and genuine unease, saying she has spent a decade reassuring other people's anxieties about pregnancy and finds it strange having her own. Her 17-hydroxyprogesterone and androstenedione, checked routinely at her last two visits, have both drifted upward compared to her pre-pregnancy baseline — not dramatically, but consistently, a pattern that fits the known physiologic reality that cortisol-binding globulin rises through pregnancy, pulling more free cortisol demand along with it, on top of whatever her CAH already asks of her replacement dose.
The actual disagreement is how aggressively to chase that number back down. Increasing her hydrocortisone dose would predictably improve her own androgen control, the same way it always has outside pregnancy — but any dose increase in a pregnant patient raises the separate, if mechanistically distinct, question of fetal glucocorticoid exposure, an association drawn mostly from research on therapeutic-dose synthetic corticosteroids given for fetal lung maturation, not physiologic-replacement-range hydrocortisone adjustment in the mother herself, where the same placental enzyme that made hydrocortisone the preferred agent in the first place is doing real, if not perfect, protective work. Naomi has no prior fetal risk for CAH herself — her husband is not a known carrier — so this is entirely about her own adrenal replacement, not prenatal treatment of an at-risk fetus.
Endocrinology follow-up, 22 weeks gestation
Her 17-OHP and androstenedione have drifted up two visits in a row — mild, but consistent, and it fits exactly what we'd expect as cortisol-binding globulin rises through pregnancy. I'd increase her hydrocortisone dose the way I would outside pregnancy if her numbers moved this way.
I'd be cautious about treating this exactly like a non-pregnant adjustment. The fetal-exposure data that raises concern about antenatal glucocorticoids is almost entirely about therapeutic-dose synthetic steroids given for lung maturation, not physiologic-range hydrocortisone adjustment in the mother — but I still don't think that difference has been directly studied enough to treat a dose increase here as risk-free. Her fetal growth is normal and her elevation is mild. I'd hold steady and recheck.
What's the drift rate, though? Two visits gives us a direction and not much else. If those numbers are climbing steadily we're having a different conversation in three weeks than we're having now, and I'd rather find that out than pre-empt it with a dose change today.
I don't think either of you is wrong about the thing you're weighting. A small increase — smaller than a full non-pregnant correction — with labs rechecked in two to three weeks instead of the usual interval, addresses the real drift without treating a mild elevation as urgent or ignoring it entirely. If it climbs further despite the modest increase, that's real information pointing toward the endocrinologist's read; if it stabilizes, we haven't over-corrected on an association drawn from a different clinical scenario.
Agreed: a modest hydrocortisone dose increase with 17-OHP and androstenedione rechecked in two to three weeks, alongside routine fetal growth monitoring. All three voices signed off on this specific plan without reservation.
The question of what her longer-term target range should look like for the rest of the pregnancy was raised but explicitly deferred, not left as a disagreement — everyone agreed that question is better answered once the recheck labs are in hand than argued over today on incomplete information.